Targeting Angiogenesis and Tumor Microenvironment in Metastatic Colorectal Cancer: Role of Aflibercept
Aflibercept in mCRC has been clinically developed in several phases I-II clinical trials and in a final phase III randomized trial. This table briefly summarizes results of efficacy, activity, and safety in published/presented clinical trials with aflibercept in mCRC.
Safety (grade 3/4 toxicities)
Yoshino et al.  Invest New Drugs 2013 Aug; 31 (4): 910–7
2–4 mg/kg + FOLFIRI
ORR ( at 4 mg/kg ): 7.7% SD: 69.2% Median PFS: 7.6 mo